Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak

BACKGROUND: Regdanvimab is a monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and a treatment option for patients with mild-to moderate coronavirus disease 2019 (COVID-19). However, there has been limited information on the clinical effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chan Mi, Park, Sang-Won, Lee, Eunyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259914/
https://www.ncbi.nlm.nih.gov/pubmed/35706081
http://dx.doi.org/10.3947/ic.2022.0011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259914/
https://www.ncbi.nlm.nih.gov/pubmed/35706081
http://dx.doi.org/10.3947/ic.2022.0011

Ejemplares similares